| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Change in fair value of warrants (note 3) | -9,846 | 2,587 | ||
| Total other income (expense), net | 9,313 | -2,929 | ||
| Loss before income tax expense (credit) | -10,042 | -26,099 | ||
| Income taxes expense | - | 118 | ||
| Income tax (credit) expense | -1,664 | 100 | ||
| Net loss | -8,378 | -26,217 | ||
| Net loss attributable to common shareholders | -8,378 | -26,217 | ||
| Net loss per common share, basic | -0.13 | -0.4 | ||
| Net loss per common share, diluted | -0.13 | -0.4 | ||
| Weighted-average number of shares used in computing net loss per common share, basic | 66,941,964 | 65,880,914 | ||
| Weighted-average number of shares used in computing net loss per common share, diluted | 66,941,964 | 65,880,914 | ||
IO Biotech, Inc. (IOBT)
IO Biotech, Inc. (IOBT)